Morrisville, N.C., September 1, 2021Clinipace, a global full-service contract research organization (CRO), and Triumph Research Intelligence (TRI), a global leader in risk-based quality management (RBQM) technology, announced they are partnering to improve the quality, efficiency, and patient safety of global clinical trials.

Regulatory authorities continue to emphasize the need for the pharmaceutical industry to adopt RBQM strategies to improve quality and provide a better way of identifying, visualizing, managing and documenting risks that may impact the outcome of clinical trials.

Clinipace have accepted this challenge and have selected TRI’s innovative new OPRA platform to support and enhance the risk management process and ensure ICH E6 (R2) compliance.

Charlene Dark stated “Clinipace have taken seriously the need to incorporate RBQM into clinical trials, not only to demonstrate ICH compliance, but because it makes sense. It enables us to incorporate both Quality by Design and Quality Management principles when delivering studies for our customers and increased safety and outcomes for our patients.”

“When it came to selecting a technology partner to support our RBQM initiative, there was only one option. We chose TRI not only because their RBQM platform, OPRA is the best on the market, but because of their operational focus. They understand what’s required to run complex global trials, which is what we do every day for our customers. For Clinipace and for TRI, it’s personal.”

“We’re delighted to have been chosen by Clinipace as their RBQM partner. Bringing together their global trial infrastructure, broad therapeutic expertise, and our innovative OPRA platform will not only deliver improved data quality and trial efficiency but also, most importantly, improved patient safety,” said Duncan Hall, CEO and founder of TRI. “More and more sponsors are realizing the benefits of RBQM and expecting their CRO partners to be able to support them in delivering improved trials in a collaborative and transparent manner. We are thrilled to be working with Clinipace and her team and look forward to continuing to grow together.”

About Clinipace:

At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. With personalized services and solutions, local regulatory expertise and therapeutic leadership, we overcome the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology, rare disease, and women’s health. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach.

About TRI:

Triumph Research Intelligence (TRI) is a leading provider of Risk-Based Quality Management (RBQM) solutions for clinical trials, based in Cambridge, UK, and Raleigh, North Carolina, in the United States. TRI was founded in 2011 by CEO Duncan Hall to address the need for a technology solution that could be used by operations teams to manage data quality, patient safety and protocol compliance from the start to the end of a clinical trial. TRI’s products, solutions, and services are designed to optimize clinical trials by improving data reliability, patient safety and operational efficiency. To find out more, visit www.tritrials.com.

Media Contact:
Clinipace
Melissa Hays
Marketing Director
MHays@clinipace.com

TRI
Neil Watkins
Chief Marketing Officer
neil.watkins@tritrials.com

Back to News